Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Significant Growth in Short Interest
by Tristan Rich · The Markets DailyInhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) saw a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 320 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 29,580 shares, the days-to-cover ratio is currently 0.0 days.
Inhibitor Therapeutics Stock Performance
Shares of Inhibitor Therapeutics stock remained flat at $0.08 during mid-day trading on Monday. 1 shares of the stock traded hands, compared to its average volume of 14,653. The firm’s 50-day simple moving average is $0.09 and its 200-day simple moving average is $0.08. The company has a market cap of $13.90 million, a price-to-earnings ratio of -8.00 and a beta of -0.73. Inhibitor Therapeutics has a twelve month low of $0.04 and a twelve month high of $0.12.
About Inhibitor Therapeutics
Inhibitor Therapeutics is a development-stage pharmaceutical company focused on investigating treatments for cancer. Its work includes repurposing itraconazole, an established antifungal medicine, for potential use in cancer treatment. The company has pursued development of itraconazole for prostate cancer and basal cell carcinoma. These are investigational uses; itraconazole’s existing approval as an antifungal does not mean it is approved to treat cancer.
Further Reading
- Five stocks we like better than Inhibitor Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions